{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Neoadjuvant+therapy&page=9", "query": { "intervention": "Neoadjuvant therapy", "page": 9 }, "page_size": 10 }, "pagination": { "page": 9, "page_size": 10, "total_count": 2079, "total_pages": 208, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Neoadjuvant+therapy&page=10&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Neoadjuvant+therapy&page=8&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-31T00:09:33.786Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01238211", "title": "Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia", "Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome", "Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11", "Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11", "Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1", "Core Binding Factor Acute Myeloid Leukemia", "Secondary Acute Myeloid Leukemia", "Therapy-Related Acute Myeloid Leukemia" ], "interventions": [ { "name": "Cytarabine", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Daunorubicin Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 61, "start_date": "2010-12-14", "completion_date": "2021-03-15", "has_results": true, "last_update_posted_date": "2023-03-01", "last_synced_at": "2026-10-31T00:09:33.786Z", "location_count": 65, "location_summary": "Lewes, Delaware • Newark, Delaware • Orlando, Florida + 44 more", "locations": [ { "city": "Lewes", "state": "Delaware" }, { "city": "Newark", "state": "Delaware" }, { "city": "Orlando", "state": "Florida" }, { "city": "Bloomington", "state": "Illinois" }, { "city": "Bloomington", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01238211" }, { "nct_id": "NCT05052671", "title": "ctDNA Assay in Patients With Resectable Pancreatic Cancer", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Pancreas Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "University of Oklahoma", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 50, "start_date": "2022-05-25", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-10-27", "last_synced_at": "2026-10-31T00:09:33.786Z", "location_count": 2, "location_summary": "Oklahoma City, Oklahoma • Tulsa, Oklahoma", "locations": [ { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Tulsa", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT05052671" }, { "nct_id": "NCT07091695", "title": "Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+Ipilimumab", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Nivolumab + relatlimab", "type": "BIOLOGICAL" }, { "name": "Nivolumab + ipilimumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2025-05-11", "completion_date": "2025-11-06", "has_results": false, "last_update_posted_date": "2025-11-12", "last_synced_at": "2026-10-31T00:09:33.786Z", "location_count": 1, "location_summary": "Dublin, Ohio", "locations": [ { "city": "Dublin", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT07091695" }, { "nct_id": "NCT00662233", "title": "Combination Chemotherapy in Treating Patients With Sarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Ovarian Cancer", "Sarcoma" ], "interventions": [ { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "ifosfamide", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "adjuvant therapy", "type": "PROCEDURE" }, { "name": "neoadjuvant therapy", "type": "PROCEDURE" }, { "name": "therapeutic conventional surgery", "type": "PROCEDURE" }, { "name": "brachytherapy", "type": "RADIATION" }, { "name": "intraoperative radiation therapy", "type": "RADIATION" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 28, "start_date": "1991-10", "completion_date": "2013-10-21", "has_results": false, "last_update_posted_date": "2018-10-09", "last_synced_at": "2026-10-31T00:09:33.786Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00662233" }, { "nct_id": "NCT06673017", "title": "PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Ductal Adenocarcinoma", "Borderline Resectable Pancreatic Adenocarcinoma", "Locally Advanced Pancreatic Adenocarcinoma", "Pancreatic Cancer" ], "interventions": [ { "name": "PTM-101", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "PanTher Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2025-04-14", "completion_date": "2028-06", "has_results": false, "last_update_posted_date": "2026-10-08", "last_synced_at": "2026-10-31T00:09:33.786Z", "location_count": 8, "location_summary": "Newport Beach, California • Miami, Florida • Detroit, Michigan + 4 more", "locations": [ { "city": "Newport Beach", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Lake Success", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06673017" }, { "nct_id": "NCT05296798", "title": "A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Locally Advanced or Metastatic Breast Cancer" ], "interventions": [ { "name": "Phesgo", "type": "DRUG" }, { "name": "Giredestrant", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "LHRH Agonist", "type": "DRUG" }, { "name": "Optional Endocrine Therapy of Investigator's Choice", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 922, "start_date": "2022-07-18", "completion_date": "2030-12-31", "has_results": false, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-10-31T00:09:33.786Z", "location_count": 10, "location_summary": "Tucson, Arizona • Los Angeles, California • Jacksonville, Florida + 7 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Annapolis", "state": "Maryland" }, { "city": "Germantown", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05296798" }, { "nct_id": "NCT04741204", "title": "Metformin Use to Reduce Disparities in Newly Diagnosed Breast Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Breast Cancer Stage", "Insulin Resistance", "Racial Bias" ], "interventions": [ { "name": "Metformin Extended Release Oral Tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Woman's", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "FEMALE", "summary": "18 Years to 80 Years · Female only" }, "enrollment_count": 0, "start_date": "2022-09", "completion_date": "2022-09", "has_results": false, "last_update_posted_date": "2023-07-06", "last_synced_at": "2026-10-31T00:09:33.786Z", "location_count": 1, "location_summary": "Baton Rouge, Louisiana", "locations": [ { "city": "Baton Rouge", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT04741204" }, { "nct_id": "NCT06396533", "title": "Increasing Pre-Surgical Identification of Muscle Invasive Tumor Evaluations Prior to Planned Cystectomy (INSITE)", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Urothelial Carcinoma", "Muscle Invasive Bladder Urothelial Carcinoma", "Non-Muscle Invasive Bladder Urothelial Carcinoma" ], "interventions": [], "intervention_types": [], "sponsor": "Fox Chase Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 92, "start_date": "2024-08-13", "completion_date": "2029-02-23", "has_results": false, "last_update_posted_date": "2025-10-31", "last_synced_at": "2026-10-31T00:09:33.786Z", "location_count": 2, "location_summary": "Omaha, Nebraska • Philadelphia, Pennsylvania", "locations": [ { "city": "Omaha", "state": "Nebraska" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06396533" }, { "nct_id": "NCT07871214", "title": "A Study to Assess The Safety and Tolerability of Pumitamig-Based Therapy Administered Before Surgery in Participants With Early-Stage Non-Small Cell Lung Cancer (ROSETTA Lung-220)", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Early-Stage Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Pumitamig", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2026-11-30", "completion_date": "2028-03-15", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-31T00:09:33.786Z", "location_count": 9, "location_summary": "Long Beach, California • Los Angeles, California • Tampa, Florida + 6 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chestnut Hill", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07871214" }, { "nct_id": "NCT00405678", "title": "Exercise Intervention Study for Early-Stage Breast Cancer Patients Receiving Neoadjuvant Therapy.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Exercise Training", "type": "BEHAVIORAL" }, { "name": "Chemo only", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 23, "start_date": "2006-09", "completion_date": "2010-09", "has_results": false, "last_update_posted_date": "2014-07-11", "last_synced_at": "2026-10-31T00:09:33.786Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00405678" } ] }